D r. George Tidmarsh, the FDA drug regulator who was placed on leave and complained of a “toxic” work environment in an ...
George Tidmarsh, the newly installed director of the FDA’s Center for Drug Evaluation and Research, was placed on leave ...
In any review of mifepristone, the FDA will now have to grapple with Judge Otake’s conclusion that the 2023 REMS decision for ...
The director of the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research, George Tidmarsh, resigned on Sunday amid serious concerns about his personal conduct, a Department of ...
Developers of biosimilars -- medicines that are near-identical copies of biologic drugs -- will no longer be required to conduct clinical trials to prove effectiveness.
Dr. George Tidmarsh, the FDA's top drug regulator, was placed on leave amid controversy over the drug approval process and a ...
FDA CDER Director George Tidmarsh resigns over controversy involving Aurinia Pharma board chair and lupus drug criticism. Read more here.
The US Food and Drug Administration will take steps to streamline the process to develop generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to ...
The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...
The Food and Drug Administration (FDA) is launching an effort to streamline the approval process for cheaper alternative “biosimilar” versions of biologic drugs as a way to curb health costs. The ...
7dOpinion
In drug trials, lack of oversight of research ethics boards could put Canadian patients at risk
Canada has no accreditation or inspection system for research ethics boards for clinical drug trials, and no oversight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback